Huang Qi, Ridout Deborah, Tsang Victor, Drury Nigel E, Jones Timothy J, Bellsham-Revell Hannah, Hadjicosta Elena, Seale Anna N, Mehta Chetan, Pagel Christina, Crowe Sonya, Espuny-Pujol Ferran, Franklin Rodney C G, Brown Kate L
Clinical Operational Research Unit, Department of Mathematics, University College London, London, United Kingdom.
Population, Policy and Practice Programme, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Ann Thorac Surg Short Rep. 2023 Dec 20;2(2):282-286. doi: 10.1016/j.atssr.2023.12.001. eCollection 2024 Jun.
Given their importance as a metric for health care evaluation, this study's aim was to evaluate the rates of surgical and catheter reinterventions for children with functionally single-ventricle (f-SV) congenital heart disease (CHD) undergoing staged palliation.
We undertook a retrospective cohort study of children born with f-SV CHD between 2000 and 2018 in England and Wales, using the national registry, with survival ascertained in 2020. Competing risk analysis was used to describe the incidence of additional procedures that occurred first, during follow-up, accounting for competing events of death or transplantation.
Of 56,039 patients who received an intervention for CHD, 3307 (5.9%) had f-SV. The largest diagnostic subcategories were hypoplastic left heart syndrome (1266 [38.3%]), tricuspid atresia (448 [13.5%]), and double-inlet left ventricle (328 [9.9%]). During a median follow-up of 5.4 (interquartile range, 0.8-10.8) years, 921 (27.9%) patients had at least 1 additional interstage surgery and 1293 (39.1%) had at least 1 additional interstage catheter intervention. The cumulative incidence of additional surgery at 6 months after stage 1 was 17.6% (95% CI, 16.2%-19.0%); at 2 years after stage 2, 8.3% (7.2%-9.5%); and at 5 years after stage 3, 8.4% (7.0%-9.9%). The cumulative incidence of additional catheter at 6 months after stage 1 was 18.0% (16.6%-19.4%); at 2 years after stage 2, 14.7% (13.3%-16.2%); and at 5 years after stage 3, 23.7% (21.5%-26.0%).
It is important to quantify additional procedures for children with f-SV disease to inform parents and health professionals, potentially facilitating the development of interventions that aim to reduce these important adverse outcomes.
鉴于手术和导管再干预率作为医疗保健评估指标的重要性,本研究旨在评估接受分期姑息治疗的功能性单心室(f-SV)先天性心脏病(CHD)患儿的手术和导管再干预率。
我们利用国家登记处对2000年至2018年在英格兰和威尔士出生的患有f-SV CHD的儿童进行了一项回顾性队列研究,并于2020年确定了其生存情况。采用竞争风险分析来描述随访期间首先发生的额外手术的发生率,并考虑死亡或移植等竞争事件。
在56039例接受CHD干预的患者中,3307例(5.9%)患有f-SV。最大的诊断亚类是左心发育不全综合征(1266例[38.3%])、三尖瓣闭锁(448例[13.5%])和双入口左心室(328例[9.9%])。在中位随访5.4年(四分位间距,0.8 - 10.8年)期间,921例(27.9%)患者至少进行了1次额外的分期手术,1293例(39.1%)患者至少进行了1次额外的分期导管干预。第1阶段后6个月时额外手术的累积发生率为17.6%(95%CI,16.2% - 19.0%);第2阶段后2年时为8.3%(7.2% - 9.5%);第3阶段后5年时为8.4%(7.0% - 9.9%)。第1阶段后6个月时额外导管干预的累积发生率为18.0%(16.6% - 19.4%);第2阶段后2年时为14.7%(13.3% - 16.2%);第3阶段后5年时为23.7%(21.5% - 26.0%)。
量化f-SV疾病患儿的额外手术对于告知家长和医疗专业人员非常重要,这可能有助于开发旨在减少这些重要不良结局的干预措施。